Satellos Bioscience Inc. (NASDAQ:MSLE) Receives Average Recommendation of “Moderate Buy” from Brokerages

Posted by ABMN Staff on Jul 15th, 2026

Shares of Satellos Bioscience Inc. (NASDAQ:MSLE – Get Free Report) have earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $19.75.

A number of research firms have recently weighed in on MSLE. Canaccord Genuity Group upgraded shares of Satellos Bioscience to a “moderate buy” rating in a report on Thursday, May 21st. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Leerink Partners assumed coverage on Satellos Bioscience in a research report on Monday, April 6th. They set an “outperform” rating and a $20.00 price target for the company. HC Wainwright upped their price target on Satellos Bioscience from $11.00 to $18.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Satellos Bioscience in a report on Monday, May 11th.

View Our Latest Analysis on MSLE

Satellos Bioscience Stock Down 1.2%

NASDAQ:MSLE opened at $9.01 on Wednesday. The company has a market cap of $187.68 million, a price-to-earnings ratio of -5.63 and a beta of 1.53. The firm’s fifty day moving average price is $7.03. Satellos Bioscience has a 52 week low of $4.64 and a 52 week high of $13.39.

Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.02). Research analysts predict that Satellos Bioscience will post -1.69 EPS for the current fiscal year.

About Satellos Bioscience

(Get Free Report)

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.